Properties of the one-dimensional Hubbard model: cellular dynamical mean-field description

The one-dimensional half-filled Hubbard model is considered at zero temperature within the cellular dynamical mean-field theory (CDMFT). By the computation of the spectral gap and the energy density with various cluster and bath sizes we examine the accuracy of the CDMFT in a systematic way, which proves the accurate description of the one-dimensional systems by the CDMFT with small clusters. We also calculate the spectral weights in a full range of the momentum for various interaction strengths. The results do not only account for the spin-charge separation, but they also reproduce all the features of the Bethe ansatz dispersions, implying that the CDMFT provides an excellent description of the spectral properties of low-dimensional interacting systems.Comment: J. Phys.: Condens. Matter, in pres

Intensive versus standard dose statin therapy: the costs and benefits for patients with acute coronary syndrome

Introduction: Recent NICE guidance in England and Wales states that statin therapy for secondary CVD should "usually be initiated with a drug with a low acquisition cost (taking into account required daily dose and product price per dose)". Intensive dose statin therapy is more costly than standard dose, but offers additional benefits and may potentially be more cost effective for a sub-group of high risk patients. Objective: To determine if the strategy of treating ACS patients with intensive dose statin compared with standard dose statin can be considered to be cost effective and to what extent these results are influenced by the age of the patient at start of treatment. Methods: A Markov model was used to explore the costs and health outcomes associated with a lifetime of intensive dose (represented by 80mg atorvastatin) versus standard dose (represented by 20mg simvastatin) treatment for patients with acute coronary syndrome. Health states included unstable angina, MI, stroke, fatal CHD, fatal stroke, or non vascular death. The benefits associated with statin treatment were modelled by applying the relative risks from a meta-analysis of 4 large RCTs reporting clinical endpoints. Costs and utilities assigned to health states were derived from a review of published evidence. Results: Treatment with intensive dose statin therapy offers additional benefits over standard dose therapy. The cost offsets through avoided events are less than the associated treatment costs and result in a cost per QALY of around £24,000 for patients with ACS starting treatment at 60 years of age and falling to around £14,000 for patients starting treatment at 70 years. The key driver of cost effectiveness is the relative risk for mortality. Conclusions: This analysis suggests that intensive statin regimens (represented by atorvastatin 80mg/day) are cost effective compared with standard statin regimens (represented by simvastatin 20mg/day) for patients with ACS over the age of 60 years. A recent registry study reports a mean age of 70 years for ACS patients admitted to UK hospitals and hence this comparison applies to the great majority of ACS patients

Upaya Mencari Gambaran Yesus yang Bercorak Ke-asia-an

Keyakinan iman orang-orang Kristen Asia akan Yesus tidak berakar kuat karena tidak lahir dari perjumpaan mereka dengan Yesus sendiri serta cenderung memisahkan mereka (komunitas Kristen Asia) dari konteks historis dan sosial-kulturalnya. Untuk menjawab pokok persoalan ini, para kristolog Asia berjuang untuk meng-Asia-kan atau mengubah kembali gambaran Yesus dengan mempergunakan ungkapan, basis budaya dan kekayaan yang terkandung di bumi Asia sendiri. Mereka menegaskan bahwa gambaran Yesus yang otentik dan relevan bagi dunia Asia hanya dapat ditemukan apabila Gereja Asia kembali kepada Yesus dan menemukan-Nya dalam realitas ganda Asia, yaitu kemiskinan yang mematahkan harapan dan religiositas yang beraneka rup

Intensive versus standard dose statin therapy: the costs and benefits for patients with acute coronary syndrome

Introduction: Recent NICE guidance in England and Wales states that statin therapy for secondary CVD should "usually be initiated with a drug with a low acquisition cost (taking into account required daily dose and product price per dose)". Intensive dose statin therapy is more costly than standard dose, but offers additional benefits and may potentially be more cost effective for a sub-group of high risk patients. Objective: To determine if the strategy of treating ACS patients with intensive dose statin compared with standard dose statin can be considered to be cost effective and to what extent these results are influenced by the age of the patient at start of treatment. Methods: A Markov model was used to explore the costs and health outcomes associated with a lifetime of intensive dose (represented by 80mg atorvastatin) versus standard dose (represented by 20mg simvastatin) treatment for patients with acute coronary syndrome. Health states included unstable angina, MI, stroke, fatal CHD, fatal stroke, or non vascular death. The benefits associated with statin treatment were modelled by applying the relative risks from a meta-analysis of 4 large RCTs reporting clinical endpoints. Costs and utilities assigned to health states were derived from a review of published evidence. Results: Treatment with intensive dose statin therapy offers additional benefits over standard dose therapy. The cost offsets through avoided events are less than the associated treatment costs and result in a cost per QALY of around £24,000 for patients with ACS starting treatment at 60 years of age and falling to around £14,000 for patients starting treatment at 70 years. The key driver of cost effectiveness is the relative risk for mortality. Conclusions: This analysis suggests that intensive statin regimens (represented by atorvastatin 80mg/day) are cost effective compared with standard statin regimens (represented by simvastatin 20mg/day) for patients with ACS over the age of 60 years. A recent registry study reports a mean age of 70 years for ACS patients admitted to UK hospitals and hence this comparison applies to the great majority of ACS patients